Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer

16 Jan 2020 01:42 0
53
OncLiveTV Download
3 0

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.

Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive

Related of "Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer" Videos